Axsome Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AXSM | ACAD | PRAX | ATAI | JAZZ | IONS | |
|---|---|---|---|---|---|---|
| Market cap | 7.21B | 3.70B | 7.95B | — | 15.06B | 6.67B |
| P/E (TTM) | — | 9.6 | — | — | 69.4 | — |
| Forward P/E | 34.0 | 23.3 | -30.0 | — | 9.1 | -35.0 |
| Price/book | 68.3 | 3.0 | 5.9 | — | 3.6 | 15.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −1.73% | −7.88% | +70.38% | — | +67.42% | −45.82% |
| Today | −1.87% | +4.38% | +1.53% | 0.00% | +2.14% | −0.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AXSM news ›Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price target boosted by stock analysts at Morgan Stanley from $247.00 to $249.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "equal…
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
Axsome Therapeutics is upgraded to Hold as valuation resets after ADA approval. Read the latest analysis on AXSM stock here. - Axsome Therapeutics is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA…
Axsome Therapeutics (NASDAQ:AXSM) Stock Gets Price Target Reduction from Robert W. Baird
Posted by Tristan Rich on Nov 3rd, 2026 Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target decreased by stock analysts at Robert W. Baird from $246.00 to $220.00 in a research note issued to investors on Tuesday,…
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Posted by Sarita Garza on Nov 3rd, 2026 Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer’s…
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
Shares of Axsome Therapeutics (AXSM) have declined nearly 20% over the past month, but Wall Street believes the selloff may be excessive despite concerns surrounding the company’s Alzheimer's disease agitation treatment launch. AXSM stock…
AxoGen (AXGN) – Analysts’ Recent Ratings Updates
Posted by Kim Johansen on Nov 3rd, 2026 A number of research firms have changed their ratings and price targets for AxoGen (NASDAQ: AXGN): AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing…
Axsome projects AUVELITY peak revenue of at least $8B as AXS-12 nears May 1, 2027 PDUFA
Axsome Q3 2026 earnings call: AUVELITY drove revenue growth as pipeline milestones near. Earnings Call Insights: Axsome Therapeutics (AXSM) Q3 2026 “Axsome delivered another robust quarter across our business, driven by continued…
AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat
Shares of Axsome Therapeutics (AXSM) fell as much as 15% on Monday to a new 52-week low as investors focused on Auvelity's launch pacing in the Alzheimer’s disease agitation (ADA) indication, despite the company’s strong third-quarter…
Axsome Therapeutics 3Q 2026: Revenue $259.7M, Net loss $12.9M, EPS $(0.25) — 10-Q Summary
TradingView - Revenue was $259.7M, compared with $171.0M in the prior-year quarter; YoY change 51.9%. - Net loss was $12.9M, compared with $47.2M in the prior-year quarter. - Nine-month revenue increased 51% ye
Axsome Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-02. The following slide deck was published by Axsome Therapeutics, Inc. The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with their 2026 Q3 earnings call.
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com9
- markets.businessinsider.com6
- marketscreener.com6
- fool.com5
- manilatimes.net4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 49 articles, not a forecast.